eligibility_summary
Eligible: non-GCB DLBCL with extranodal involvement, measurable disease (node ≥15 mm, extranodal ≥10 mm), ECOG 0–2, EF ≥50%, CrCl ≥30 mL/min, AST/ALT ≤3×ULN, platelets ≥50×10^9/L, Hb ≥8 g/dL, ANC ≥1.0×10^9/L, life expectancy ≥3 mo, contraception. Exclude: recent major surgery, primary mediastinal/CNS lymphoma, prior indolent lymphoma, active malignancy, recent ICH/warfarin, strong/mod CYP3A inducers, anthracycline >150 mg/m², major CV/lung disease, HIV/active HBV/HCV, uncontrolled infection, pregnant/breastfeeding, investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in newly diagnosed untreated non-GCB DLBCL with extranodal disease testing polatuzumab vedotin + zanubrutinib with R‑CHP. Polatuzumab vedotin: antibody–drug conjugate to CD79b delivering MMAE (microtubule inhibitor) to B cells, causing mitotic arrest/apoptosis. Zanubrutinib: oral small-molecule BTK inhibitor that blocks B-cell receptor signaling (downstream NF-κB/MAPK), relevant in non-GCB DLBCL. Rituximab: anti-CD20 monoclonal antibody mediating ADCC/CDC and direct apoptosis of B cells. Cyclophosphamide: alkylating agent causing DNA crosslinks. Doxorubicin: anthracycline/topoisomerase II inhibitor and ROS generator. Prednisone: glucocorticoid with lympholytic effects. Cells/pathways targeted: malignant B cells via CD79b and CD20, BTK/BCR signaling, microtubules, DNA damage/Topo II, glucocorticoid-induced apoptosis.